Background: Ayurveda is an ancient system of medicine popularly practiced in India.
INTRODUCTION
In India out of a population of 1.3 billion, over 60 million patients are suffering from DM. The number of patients of diabetes is expected to increase to 109 million by 2035 out of an estimated population of 1.5 billion. 1 Diabetes mellitus (DM) appear to have a lot of similarities in etiological factors, classification, clinical symptoms, complications and treatment modalities with Madhumeha amongst the twenty types of Prameha described in Ayurveda.
Over the time, DM can increase the risk of heart disease and stroke, cause neuropathy, retinopathy, and nephropathy. Morbidity and mortality from cardiovascular disease are two to five times higher in persons with diabetes. 2 Type I DM is managed with insulin injections, 3 and type II DM may be treated with medications. Metformin is generally recommended as a first-line treatment for type II diabetes.
JRAS
Nowadays with increased reporting of toxicity of drugs have been acknowledged after meta-analysis of multiple clinical trial data [5] [6] [7] assurance regarding the safety of drugs is a prime concern for health conscious people. Drug resistance, hypersensitivity with insulin, drug intolerance, and fear to hypo and hyperglycemic episode with drugs are certain setbacks of anti-diabetic modern medicines. [8] [9] [10] [11] Pramehaghna Ayurveda drugs have Rasayana (rejuvinative), Tridosha Shamaka, Lekhana properties by which Ayurvedic drugs are efficacious and most importantly safe so as to maintain overall health in people with diabetes. Ayurvedic drugs hence may suffice in the long-term management of DM. 12 But sometimes sporadic incidences regarding the toxicity of Ayurvedic herbo-mineral drugs are reported , 13 and it is observed that the drugs consumed were usually not standardized. A study reported that one-fifth of both US manufactured and Indian-manufactured Ayurvedic medicines purchased via the Internet contained detectable lead, mercury, or arsenic. 13 In rebuttal through a press release, Ministry of AYUSH (then Department of AYUSH, Ministry of Health and Family Welfare) mentioned that there are many flaws and bias in reporting the study and it was observed that the medicines were sold through the internet, which does not indicate the source of their origin. 
MATERIALS AND METHODS
The detail study protocol, information about the trialed drugs and analyzed data of four clinical studies were assessed. The studies were conducted under IMR (intra mural research) program of CCRAS and they are: The participants of all the studies were informed about the study procedures. The eligibility criteria were checked precisely, and informed consent forms were also signed by the participants before their enrolment in the study. The formulations fulfilling the physicochemical standards and quality parameters were procured from good manufacturing practice (GMP) certified Ayurveda pharmaceutical companies complying the standard operative procedures for the preparations of the trial drugs mentioned in Ayurvedic pharmacopeia of India. In all the studies the trial drugs were administered for 84 days. 
Selection Criteria of the Participants

Inclusion Criteria
Participants of either sex aged between 30 to 65 years, who were diagnosed to be type-II DM by either having glycosylated haemoglobin (HbA1c) ≥ 6.5% or fasting blood sugar (BS-F) > 126 mg% or post prandial blood sugar (BS-PP) >200 mg% or diabetics who were on lifestyle modifications (on diet management and physical exercise) or subjects who were on tablet metformin (up to 2 gm/ day) and who were willing to participate in the clinical trial for 14 weeks were included in the study.
Exclusion Criteria
Patients suffering from the complications of diabetes like diabetic neuropathy, diabetic nephropathy, and diabetic retinopathy; past history of atrial fibrillation, acute coronary syndrome, myocardial infarction, stroke or severe arrhythmia in the last six months, uncontrolled hypertension (>160/100 mm of Hg); major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Psycho-Neuro-Endocrinal disorders, etc.); prolonged (> 6 weeks) medication with corticosteroids, antidepressants, anticholinergics, severe renal or hepatic disorders; evidence of malignancy; alcoholics and/or drug abusers; history of hypersensitivity to any of the trial drugs or their ingredients; pregnant and lactating woman, woman on oral contraceptives therapy and who completed participation in any other clinical trial during the past six months or other conditions as per the Investigator may jeopardize the study were excluded from the trial.
A brief description of studies conducted for the management of DM is given in Table 1 . 
Detailed Profile of Study Interventions
Study Procedures
In all the studies, at baseline, the detail demographic data, Prakriti (body constitution) of all the enrolled participants were collected in the case record form. The trial medicines were dispensed at each visit and follow up was done every two weeks to record the onset of any adverse drug reaction/adverse events during the 84 days of the treatment period. Clinical assessment through diabetes symptoms score (DSQ) assessed with the help of VAS (0-10), health-related quality of life (HRQoL) recorded at baseline and end of the 84th day by using RAND, 36 items short form health survey (SF-36) questionnaire.
Safety Assessment
Clinical safety was assessed based on the safety laboratory parameters i.e. assessment of liver function and kidney functions at the baseline and end of the intervention period (i.e. 84 days) in each study. Further, the data on 
RESULTS
The data of 144, 187, 189 and 50 participants were analyzed for the study no. 1, 2, 3, and 4 respectively. The demographic profiles viz. gender, education, socio-economic status, dietetic habit, Prakriti, etc. of the participants are summarized in Table 2 .
Effect of the Drugs on Vital Parameters
The blood pressure, pulse rate, etc. were analyzed and found that there are no abnormal changes in these parameters at the end of the treatment. The details are presented in Table 3 .
Effect of the Trial Drugs on Safety Laboratory Parameters
The safety laboratory parameters like liver function test and kidney function tests were carried out in all the studies at baseline and at the end of the treatment to know the clinical safety of trial drugs. The detail data of each study are presented in Tables 4 and 5 .
DISCUSSION
The study aimed to assess the safety of Ayurvedic formulations viz. reporting of adverse drug reactions or adverse events by the study participants were observed during the study period. Moreover, no adverse events by metformin interaction with the Ayurvedic formulations Saptavimshatika Guggulu and Haridra Churna and Nisha Amalaki and Chandraprabha Vati was reported in the subjects who were on metformin upto 2gm/day during the study.
For Saptavimshatika Guggulu and Haridra churna, most of the safety parameters were found to be statistically significant. Serum uric acid, creatinine, urea, total protein, and albumin were found to be statistically insignificant. For Nisha Amalaki and Chandraprabha Vati, serum uric acid and serum cholesterol were found to be statistically significant, and all other safety parameters were in normal range. For Nisha Katakadi Kashaya and Yashada Bhasma, all the safety parameters were found in the normal range during the study, and there was no significant change observed in Renal function test, Liver function test when compared with baseline data to end of treatment within the group and also in comparison among the three groups. For Gokshuradi Guggulu and Guduchi Churna Blood sugar and aspartate aminotransferase (AST) is found to be statistically significant while other safety parameters are found to be in normal range.
In the present study, both herbal and herbomineral formulations are administered. Saptavinshatika Guggulu, Chandraprabha Vati and Yashada Bhasma are herbomineral formulations while Haridra Churna, Nisha Amalaki, Nisha Katakadi Kashaya, Gokshuradi Guggulu, and Guduchi Churna are herbal formulations. Ayurveda emphasizes mainly on safe treatment and hence factors like Prakriti (constitution), Guna (properties), Karma(actions), Prabhava (effect), Desha (habitat), 24 Ritu (Season/time of collection), 25 Part of plant used for collection, 26 method of collection, 27 storage of collected drugs 28 and afterwards their pharmaceutical processing is considered before preparing herbal formulations. By taking into account all these factors along with enhancement of potency of the drug it is made fit for 29 It is by proper processing that even a poisonous or Tikshna drug can be converted into an excellent medicine. 30 Description regarding time 31 and route of drug administration 32 are also found in Ayurveda classics which are equally important to obtain maximum benefits without any untoward effects. To ensure and enhance the quality of Ayurveda medicines, the government of India has notified GMP under schedule T of the Drugs and Cosmetics Act, 1940 which also ensures raw materials used in the manufacture of drugs are authentic, of prescribed quality and are free from the pathogen. Medicaments are prepared in Ayurveda after carefully assessing the combined effect, time effect, analytical approach and modification of original qualities. Mineral drugs viz. Makshika, Yashada, Loha and Shilajita, in the herbo-mineral formulation administered, are purified and prepared as Bhasmas through certain strict procedures such as Shodhana (purification and processing) and Marana (incineration). 33 The Bhasmas prepared are examined as per certain criteria mentioned and then in small doses, are used in Ayurveda formulations. The adverse drug reactions for herbo-mineral formulations (Bhasmas) described in Ayurveda appear only if the stringent procedures for manufacturing and certain precautionary measures mentioned in Ayurveda are not followed properly. Any complications could be observed if the drug is too old and reached its expiry date or is not prepared properly or because of improperly given Samskars. 34 Hence the findings of study corroborate that the herbal and herbomineral Ayurvedic formulations assessed in the four clinical studies for the management of DM are clinically safe and effective.
CONCLUSION
The findings of the present study suggest that the Ayurveda formulations viz. 
